Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion - CNBC
Gilead Sciences will pay as much as $7.8 billion to acquire partner Arcellx in its largest deal since 2020, the biopharma company said on Monday.
Search Group
Share To
Comments
About Screade
Screade® Inc. version db7c534, copyright 2016 - 2026
Blocked Users
Customize Dark Theme
Forgot your password?
Forgot your password?
Invite your friends
Please type emails of people you want to invite, we will send them invitation email on your behalf. Separate emails with comma if you want to invite multiple friends.
Comments